IVIG is NOT Indicated for Post-Septic Hepatitis
IVIG should not be used for hepatitis developing after sepsis, as high-quality evidence shows no mortality benefit in sepsis itself, and IVIG can actually cause hepatitis as a direct adverse effect. 1, 2, 3
Primary Recommendation Against IVIG Use
The Surviving Sepsis Campaign guidelines explicitly recommend against routine IVIG therapy for sepsis or septic shock in both adults and children, based on high-quality randomized controlled trials showing no mortality benefit. 2, 3
When restricted to high-quality studies with low risk of bias, IVIG demonstrates no reduction in mortality (relative risk 0.97; 95% CI 0.81-1.15). 1, 2
The largest randomized controlled trial (n=624) found no effect of IVIG on sepsis outcomes. 1, 3
Critical Safety Concern: IVIG Can Cause Hepatitis
IVIG itself is a documented cause of non-A, non-B hepatitis, with one study showing 21% (16 of 77 patients) developed hepatitis from IVIG infusions, with 5 deaths where hepatitis was either causative or contributory. 4
The hepatitis associated with IVIG can progress to chronic active hepatitis and cirrhosis, with elevated liver enzymes and alkaline phosphatase. 4
This hepatotoxicity occurred across multiple batches and preparations, indicating it is not an isolated contamination issue but rather an inherent risk of the therapy. 4
Why Post-Septic Hepatitis Does Not Change the Recommendation
Post-septic hepatitis is typically a manifestation of sepsis-induced organ dysfunction or hypoperfusion injury, not a separate indication for IVIG. 3
There is no evidence that IVIG treats hepatitis of any etiology in the sepsis context—in fact, it may worsen liver injury. 4
The most recent evidence (2025) confirms that even in XDR pathogen-induced sepsis, IVIG does not reduce 30-day mortality (71.4% vs 77.3%, P=0.886) or ICU length of stay. 5
Exceptions Where IVIG Might Be Considered (Not Applicable Here)
Toxic shock syndrome, particularly streptococcal etiology. 2, 3
Primary humoral immunodeficiencies or documented low immunoglobulin levels requiring replacement therapy. 2, 3
Necrotizing fasciitis (though evidence is inconsistent). 3
None of these exceptions apply to post-septic hepatitis.
Common Pitfalls to Avoid
Do not rely on older meta-analyses that included low-quality studies showing benefit—these findings disappear when only rigorous trials are analyzed. 1, 2
Do not assume IgM-enriched preparations are superior; when restricted to high-quality trials, even these show no mortality benefit. 1, 2
Do not administer IVIG hoping to "support" the immune system in a patient with organ dysfunction—this lacks evidence and carries hepatotoxic risk. 6, 4